Ab Initio Biotherapeutics


Ab Initio Biotherapeutics operates as an antigen-discovery company. Its proprietary antigen discovery platform allows for targeting multi-transmembrane proteins such as GPCRs and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders.

Industries

biotechnology
health-care
medical

Nr. of Employees

small (1-50)

Ab Initio Biotherapeutics

South San Francisco, California, United States, North America


Patents

SIRP-gamma polypeptide compositions and treatment of cancer

US-11407801-B2

View Details

SIRP-gamma polypeptide compositions and methods of use

US-10774125-B2

View Details

SIRP polypeptide compositions and methods of use

US-9845345-B2

View Details

Products

Antibody Optimization

A process that uses engineered animals with human Ig transgenes to generate antibodies with optimal binding characteristics for therapeutic use.

OmniAb Discovery Platform

A platform providing access to diverse antibody repertoires and high-throughput screening technologies for discovering next-generation therapeutics using transgenic animals.

Phenotypic Sampling of the Immune Repertoire

A method to identify antibodies in immunized animals using single B-cell screening, allowing for the recovery of desired mAb clones and efficient immune repertoire sampling.

OmniRat

A transgenic rat platform generating human antibodies for therapeutic development, including monospecific and bispecific antibodies.

OmniMouse

A transgenic mouse platform delivering fully human antibodies using standard mouse-based protocols.

Diving Deeper into Immune Repertoires

An approach to expand candidate pools by further phenotypic screening and using NGS data to explore antibody repertoires for related sequences.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.